Despite major interest in this pathway for cancer drug discovery, no drugs have yet been approved that act specifically against PI3K or its downstream regulator, AKT. However, several drugs that ...

The phosphatidylinositol-3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signaling (PAM) pathway is a critical intracellular pathway involved in various cellular functions ...

The mechanism of action may be associated with upregulation of the IRS1/PI3K/AKT signaling pathway and inhibition of IRS1 phosphorylation. Type 2 diabetes mellitus (T2DM) is a metabolic disease with a ...

International Cooperation Base for Active Substances in Traditional Chinese Medicine in Hubei Province, School of Pharmaceutical Sciences, South-Central Minzu University, 182 min-Zu Road, Wuhan 430074 ...

Eosinophils play a crucial role in allergic responses, secreting cytokines and inflammatory mediators that exacerbate AR ...

The following is a summary of “Mendelian randomization of plasma proteomics identifies novel ALS-associated proteins and their GO enrichment and KEGG pathway analyses,” published in the March 2025 ...

Celcuity's gedatolisib, a dual PI3K/mTOR inhibitor, shows promise in Phase 3 breast cancer trials. Click here to read an analysis of CELC stock now.

Hepatic ischemia-reperfusion injury (IRI) is a common and unavoidable complication associated with liver transplants that may ...

Researchers from SRM Institute of Science and Technology, led by Dr. KN Aruljothi, have published a study in ExRNA ...

Leading oncologists discuss the role of PI3K/AKT inhibitors in breast cancer treatment, highlighting INAVO120 trial data, the importance of early genetic testing, and side-effect management.

Colorectal cancer (CRC) is one of the most common and deadly cancers worldwide, accounting for nearly 10% of all cancer cases. It is the second leading cause of cancer-related deaths, with around one ...